Gene · 3148
HMGB2: high mobility group box 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HMGB2: high mobility group box 2. Genes, record 3148. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3148
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P26583 | High mobility group protein B2 | 209 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents145
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4709870 A1 | 2026-03-18 | 30 | P26583 | Espacenet |
| JP 2026016462 A | 2026-02-03 | 67 | P26583 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 49087 | P26583 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 49088 | P26583 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 49089 | P26583 | Espacenet |
| JP 2026000906 A | 2026-01-06 | 144 | P26583 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3731 | P26583 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4740 | P26583 | Espacenet |
| JP 2025148518 A | 2025-10-07 | 17 | P26583 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 3731 | P26583 | Espacenet |
1 to 10 of 145
See all 145 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,269
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HMGB2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| R01AI032524 | Mechanism and Regulation of V(D)J Recombination | 8 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 5 | 2025 |
| R01CA093729 | Repair of Genome Destabilizing DNA Structures | 5 | 2025 |
| R35GM128854 | Chemical and Molecular Mechanisms of Mitochondrial DNA Degradation | 5 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 4 | 2025 |
| P30ES013508 | Center of Excellence in Environmental Toxicology | 4 | 2025 |
| P30AI060354 | Harvard University Center for AIDS Research | 3 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,269Source NIH's project files
See all 1,269 nih grantsPapers1,965
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An extramedullary bone model of metastatic dormancy reveals an increased rate of metastatic reactivation upon distant insults. | Cell Rep | 2026 | 42822459 | PubTator, text mining | PubMed |
| An IGF2BP2-MYBL2-HMGB2 Signaling Axis Promotes Macrophage Immune Evasion in Hepatocellular Carcinoma. | Cancer Commun (Lond) | 2026 | 42819712 | PubTator, text mining | PubMed |
| Synergistic antitumor effect of HMGB2 targeting combined with MDM2 inhibitor in diffuse intrinsic pontine glioma therapy. | Front Oncol | 2026 | 42812154 | PubTator, text mining | PubMed |
| Post-transcriptional regulation maintains neurogenic potential of human neural progenitor cells. | Stem Cell Reports | 2026 | 42753731 | PubTator, text mining | PubMed |
| Admission whole-blood transcriptomic characterization of a neutrophil-predominant systemic immune response in patients with acute traumatic brain injury. | Shock | 2026 | 42735045 | PubTator, text mining | PubMed |
| HMGB2 Impacts Cisplatin-Induced DNA Adduct Processing in Chemoresistant Ovarian Cancer Cells. | Genes (Basel) | 2026 | 42650109 | PubTator, text mining | PubMed |
| Extracellular Vesicle miR-558 Regulates Endothelial Function Through HMGB2 in Adult Moyamoya Disease. | Cells | 2026 | 42645183 | PubTator, text mining | PubMed |
| Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. | Cell Rep | 2026 | 42636797 | PubTator, text mining | PubMed |
| KDM6A suppresses proliferation and epithelial-mesenchymal transition in prostate cancer cells. | Urol Oncol | 2026 | 42636791 | PubTator, text mining | PubMed |
| Development and validation of cell-free RNA-based predictive models for preeclampsia using placental single-cell transcriptomic data. | J Reprod Immunol | 2026 | 42623724 | PubTator, text mining | PubMed |
1 to 10 of 1,965
See all 1,965 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3148
GET https://conductscience.org/api/genes/v1/3148/patents?page=2